🇺🇸 FDA
Pipeline program

BMN 701

701-301

Phase 3 small_molecule terminated

Quick answer

BMN 701 for Late-onset Pompe Disease is a Phase 3 program (small_molecule) at BIOMARIN PHARMACEUTICAL INC with 1 ClinicalTrials.gov record(s).

Program details

Company
BIOMARIN PHARMACEUTICAL INC
Indication
Late-onset Pompe Disease
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials